📊 TOIIW Key Takeaways
Is Oncology Institute, Inc. (TOIIW) a Good Investment?
Despite impressive 27.8% YoY revenue growth, Oncology Institute exhibits severe financial distress with negative stockholders equity (-$15.7M), persistent operating losses (-$36.1M), and negative operating cash flow (-$24.6M), indicating the company cannot sustain operations profitably. The deteriorating net income (-20.5% YoY), inability to service debt (interest coverage of -267.3x), and ongoing cash burn of $27.8M in free cash flow threaten long-term viability despite $33.6M in remaining cash.
Oncology Institute, Inc. Key Strengths (TOIIW)
- Strong top-line revenue growth of 27.8% YoY ($502.7M)
- Adequate short-term liquidity with 1.59x current ratio and $33.6M cash balance
- Operating in growing healthcare services sector with demographic tailwinds
TOIIW Stock Risks: Oncology Institute, Inc. Investment Risks
- Technical insolvency with negative stockholders equity of -$15.7M (liabilities exceed assets)
- Negative operating cash flow (-$24.6M) and free cash flow (-$27.8M) indicating unsustainable operations
- Inability to service debt with interest coverage ratio of -267.3x and $77.4M long-term debt burden
- Deteriorating profitability with net losses of -$60.6M and worsening net margin of -12.1%
- Revenue growth not translating to profitability (EPS worsened despite revenue expansion)
- Limited cash runway at current burn rate; likely requires capital raise or restructuring
Key Metrics to Watch
- Quarterly trend in operating cash flow toward positive territory
- Path to EBITDA and operating income breakeven
- Debt restructuring announcements or covenant violations
- Cash balance and estimated runway months
- Gross margin expansion and cost structure improvements
Oncology Institute, Inc. (TOIIW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Oncology Institute, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
TOIIW Profit Margin, ROE & Profitability Analysis
TOIIW vs Services Sector: How Oncology Institute, Inc. Compares
How Oncology Institute, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oncology Institute, Inc. Stock Overvalued? TOIIW Valuation Analysis 2026
Based on fundamental analysis, Oncology Institute, Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oncology Institute, Inc. Balance Sheet: TOIIW Debt, Cash & Liquidity
TOIIW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oncology Institute, Inc.'s revenue has grown significantly by 148% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.71 indicates the company is currently unprofitable.
TOIIW Revenue Growth, EPS Growth & YoY Performance
TOIIW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $104.4M | -$2.5M | $-0.02 |
| Q3 2025 | $99.9M | -$15.5M | $-0.14 |
| Q2 2025 | $98.6M | -$15.5M | $-0.15 |
| Q1 2025 | $94.7M | -$19.6M | $-0.21 |
| Q3 2024 | $82.0M | -$15.5M | $-0.18 |
| Q2 2024 | $80.2M | -$15.5M | $-0.17 |
| Q1 2024 | $76.2M | -$19.9M | $-0.22 |
| Q3 2023 | $65.0M | -$2.7M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Oncology Institute, Inc. Dividends, Buybacks & Capital Allocation
TOIIW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oncology Institute, Inc. (CIK: 0001799191)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TOIIW
What is the AI rating for TOIIW?
Oncology Institute, Inc. (TOIIW) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TOIIW's key strengths?
Claude: Strong top-line revenue growth of 27.8% YoY ($502.7M). Adequate short-term liquidity with 1.59x current ratio and $33.6M cash balance.
What are the risks of investing in TOIIW?
Claude: Technical insolvency with negative stockholders equity of -$15.7M (liabilities exceed assets). Negative operating cash flow (-$24.6M) and free cash flow (-$27.8M) indicating unsustainable operations.
What is TOIIW's revenue and growth?
Oncology Institute, Inc. reported revenue of $502.7M.
Does TOIIW pay dividends?
Oncology Institute, Inc. does not currently pay dividends.
Where can I find TOIIW SEC filings?
Official SEC filings for Oncology Institute, Inc. (CIK: 0001799191) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TOIIW's EPS?
Oncology Institute, Inc. has a diluted EPS of $-0.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TOIIW's fundamental grade?
Based on our AI fundamental analysis in June 2026, Oncology Institute, Inc. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TOIIW stock overvalued or undervalued?
Valuation metrics for TOIIW: ROE of N/A (sector avg: 16%), net margin of -12.1% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is TOIIW's AI grade for 2026?
Our dual AI analysis gives Oncology Institute, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TOIIW's free cash flow?
Oncology Institute, Inc.'s operating cash flow is $-24.6M, with capital expenditures of $3.2M. FCF margin is -5.5%.
How does TOIIW compare to other Services stocks?
Vs Services sector averages: Net margin -12.1% (avg: 10%), ROE N/A (avg: 16%), current ratio 1.59 (avg: 1.5).